gene

DR5

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about DR5: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

106Connections

0Hypotheses

0Analyses

50Outgoing

38Incoming

0Experiments

0Debates

Summary

DR5 is a gene implicated in neurodegeneration research. Key relationships include: therapeutic target, inhibits, activates. Associated with ALS, Als, Breast Cancer. Connected to 59 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	DR5
Chromosome	4p16.1
Protein Type	Receptor
Function	is an important component in the neurobiology of neurodegenerative diseases.
Molecular Weight	52.9 kDa
Amino Acids	477 aa
Pathways	Akt, Apoptosis, Cell Cycle, Pi3K
UniProt ID	P21918
NCBI Gene ID	1816
Ensembl ID	ENSG00000169679
GeneCards	DR5
Human Protein Atlas	DR5
N-terminal extracellular domain	Contains glycosylation sites, involved in ligand binding
Transmembrane domains (TM1-TM7)	Form the binding pocket for dopamine and synthetic ligands
Three extracellular loops (ECL1-ECL3)	Modulate ligand access and receptor conformation
Associated Diseases	ALS
Interactions	AKT, AND, APOPTOSIS, BAD, BCL-2, CANCER
KG Connections	106 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: DR5 — AlphaFold P21918 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (1)

Knowledge base pages for this entity

Canonical Page

DRD5 Gene — Dopamine Receptor D5

gene · 1940 words

→

Pathway Diagram

graph TD
    DR5["DR5"]
    Cancer{"Cancer"}
    DR5 -->|"activates"| Cancer
    Tumor{"Tumor"}
    DR5 -->|"activates"| Tumor
    Als{"Als"}
    DR5 -->|"inhibits"| Als
    DR5 -->|"activates"| Als
    Lymphoma{"Lymphoma"}
    DR5 -->|"therapeutic target"| Lymphoma
    DR5 -->|"therapeutic target"| Als
    Ms{"Ms"}
    DR5 -->|"therapeutic target"| Ms
    DR5 -->|"therapeutic target"| Cancer
    ALS{"ALS"}
    DR5 -->|"inhibits"| ALS
    EGFR["EGFR"]
    DR5 -->|"activates"| EGFR
    BAD["BAD"]
    DR5 -->|"inhibits"| BAD
    Pi3K(["Pi3K"])
    DR5 -->|"inhibits"| Pi3K
    JUN["JUN"]
    JUN -->|"inhibits"| DR5
    ERK["ERK"]
    ERK -->|"inhibits"| DR5
    PI3K["PI3K"]
    PI3K -->|"inhibits"| DR5
    EGFR -->|"activates"| DR5
    BAD -->|"inhibits"| DR5
    AKT["AKT"]
    AKT -->|"activates"| DR5
    C_JUN["C-JUN"]
    C_JUN -->|"activates"| DR5
    P53["P53"]
    P53 -->|"therapeutic target"| DR5
    CANCER["CANCER"]
    CANCER -->|"therapeutic target"| DR5
    APOPTOSIS["APOPTOSIS"]
    APOPTOSIS -->|"therapeutic target"| DR5
    style DR5 fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (68)

Target	Relation	Type	Str
Cancer	therapeutic_target	disease	0.75
Als	inhibits	disease	0.65
Breast Cancer	therapeutic_target	disease	0.65
ALS	inhibits	disease	0.65
Tumor	therapeutic_target	disease	0.65
Als	activates	disease	0.65
Cancer	inhibits	disease	0.65
Lymphoma	inhibits	disease	0.65
ALS	activates	disease	0.65
Ms	therapeutic_target	disease	0.65
Cancer	activates	disease	0.65
Lymphoma	therapeutic_target	disease	0.65
Tumor	activates	disease	0.65
Als	therapeutic_target	disease	0.65
P53	activates	gene	0.60
P21	activates	gene	0.60
T Cell	inhibits	cell_type	0.60
AND	inhibits	gene	0.60
CANCER	inhibits	gene	0.60
APOPTOSIS	activates	gene	0.60
BCL-2	inhibits	gene	0.60
P53	inhibits	gene	0.60
FOXO	inhibits	gene	0.60
HER2	activates	gene	0.60
B Cell	therapeutic_target	cell_type	0.60
ALS	associated_with	disease	0.60
Akt	inhibits	pathway	0.60
Egfr	activates	protein	0.60
EGFR	activates	gene	0.60
BAD	inhibits	gene	0.60
AKT	inhibits	gene	0.60
JUN	activates	gene	0.60
PI3K	activates	gene	0.60
PI3K	inhibits	gene	0.60
JUN	inhibits	gene	0.60
JNK	inhibits	gene	0.60
TRAIL	therapeutic_target	gene	0.60
TRAIL	activates	gene	0.60
CASP8	activates	gene	0.60
TNF	activates	gene	0.60
MDM2	activates	gene	0.60
TRAIL	inhibits	gene	0.60
Pi3K	inhibits	pathway	0.60
Apoptosis	inhibits	pathway	0.60
C-JUN	inhibits	gene	0.60
ERK	activates	gene	0.60
Akt	activates	pathway	0.60
Apoptosis	activates	pathway	0.60
Cell Cycle	activates	pathway	0.60
Pi3K	activates	pathway	0.60

Incoming (38)

Source	Relation	Type	Str
CANCER	therapeutic_target	gene	0.70
BCL-2	therapeutic_target	gene	0.70
MEK	inhibits	gene	0.60
CANCER	activates	gene	0.60
FOXO	inhibits	gene	0.60
BCL-2	inhibits	gene	0.60
CANCER	inhibits	gene	0.60
P53	inhibits	gene	0.60
JUN	inhibits	gene	0.60
PI3K	inhibits	gene	0.60
EGFR	activates	gene	0.60
BAD	inhibits	gene	0.60
AKT	activates	gene	0.60
CD44	therapeutic_target	gene	0.60
STAT3	therapeutic_target	gene	0.60
ABCG2	therapeutic_target	gene	0.60
ABCB1	therapeutic_target	gene	0.60
RAB7A	activates	gene	0.60
TNFSF10	activates	gene	0.60
TNFRSF1A	activates	gene	0.60
FYCO1	activates	gene	0.60
AKT	inhibits	gene	0.60
JNK	inhibits	gene	0.60
TRAIL	inhibits	gene	0.60
ERK	inhibits	gene	0.60
C-JUN	activates	gene	0.60
P53	therapeutic_target	gene	0.60
APOPTOSIS	therapeutic_target	gene	0.60
HIF	therapeutic_target	gene	0.60
IL-6	therapeutic_target	gene	0.60
JAK	therapeutic_target	gene	0.60
AND	therapeutic_target	gene	0.60
AND	activates	gene	0.60
APOPTOSIS	activates	gene	0.60
HER2	activates	gene	0.60
APOPTOSIS	inhibits	gene	0.60
MUTANT P53	inhibits	gene	0.60
C-JUN	inhibits	gene	0.60

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (0)

Multi-agent debates referencing this entity

No debates reference this entity

Related Research

Hypotheses and analyses mentioning DR5 in their description or question text

No additional research found